Updates for VA Clinicians in the Use of Bispecific Antibodies Across Later-Line Non-Hodgkin’s Lymphomas:
Summarizing Current Efficacy and Safety Data
Bi-specific antibodies for Non-hodgkin’s lymphoma treatment in Veterans Affairs patients: Current treatments, limitations and new promises
Post-Test/Evaluation

Exit Survey
Questions marked with a * are required
21%
Contact Information
Credentials/Degree (MD, DO, etc.)
Date of  Participation
A 65-year-old male veteran presents with diffuse large B-cell lymphoma (DLBCL). Which of the following would be an indicator for prescribing a bispecific antibody?
Which of the following receptors do the FDA-approved or trial bi-specific antibodies for treating NHL recognize?
Obinutuzumab pretreatment for cytokine release syndrome (CRS) mitigation is administered for which of the following bispecific antibodies?
Powered by QuestionPro